Faron Pharmaceuticals Oy Cash Flow Conversion Efficiency
Faron Pharmaceuticals Oy cash flow conversion efficiency. Based on the latest financial reports, Faron Pharmaceuticals Oy (FARN) has a cash flow conversion efficiency ratio of 0.000x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-5.21K ≈ $-0.63 USD) by net assets (GBX-16.25 Million ≈ $-1.98K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Faron Pharmaceuticals Oy (2012–2024)
Cash flow conversion efficiency of Faron Pharmaceuticals Oy from 2012 to 2024. This chart illustrates how Faron Pharmaceuticals Oy's cash flow conversion efficiency has evolved over time, based on yearly financial data. View FARN live share price for real-time trading data and today's change.
Faron Pharmaceuticals Oy Cash Flow Conversion Ratio Explained
Faron Pharmaceuticals Oy cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Faron Pharmaceuticals Oy Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Faron Pharmaceuticals Oy ranked by their cash flow conversion efficiency. Also see FARN stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AFFINOR GROWERS INC.
F:1AF0
|
0.027x |
|
Dewata Freight International Tbk PT
JK:DEAL
|
0.041x |
|
Sleep Number Corp
NASDAQ:SNBR
|
0.012x |
|
Devolver Digital Inc
LSE:DEVO
|
0.146x |
|
Black Widow Resources Inc
V:BWR
|
-0.006x |
|
CABASSE S.A. EO -50
F:LB0
|
N/A |
|
Leslie's, Inc.
NASDAQ:LESLQ
|
-0.201x |
|
DETALION GAMES SA ZY -10
F:9XJ
|
0.001x |
Annual Cash Flow Conversion Efficiency for Faron Pharmaceuticals Oy (2012–2024)
The table below shows the annual cash flow conversion efficiency of Faron Pharmaceuticals Oy from 2012 to 2024. Review FARN FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX-9.76 Million ≈ $-1.19K |
GBX-22.97 Million ≈ $-2.79K |
2.353x | +49.86% |
| 2023-12-31 | GBX-15.16 Million ≈ $-1.84K |
GBX-23.81 Million ≈ $-2.90K |
1.570x | -21.63% |
| 2022-12-31 | GBX-11.48 Million ≈ $-1.40K |
GBX-22.99 Million ≈ $-2.80K |
2.004x | +126.31% |
| 2021-12-31 | GBX2.92 Million ≈ $355.04 |
GBX-22.22 Million ≈ $-2.70K |
-7.614x | -180.55% |
| 2020-12-31 | GBX-1.85 Million ≈ $-224.97 |
GBX-17.48 Million ≈ $-2.13K |
9.453x | +232.08% |
| 2019-12-31 | GBX1.61 Million ≈ $195.89 |
GBX-11.52 Million ≈ $-1.40K |
-7.157x | -12767.17% |
| 2018-12-31 | GBX369.00K ≈ $44.90 |
GBX-20.52K ≈ $-2.50 |
-0.056x | +98.56% |
| 2017-12-31 | GBX4.74 Million ≈ $577.09 |
GBX-18.36 Million ≈ $-2.23K |
-3.872x | -398.52% |
| 2016-12-31 | GBX10.88 Million ≈ $1.32K |
GBX-8.45 Million ≈ $-1.03K |
-0.777x | -21.48% |
| 2015-12-31 | GBX11.18 Million ≈ $1.36K |
GBX-7.15 Million ≈ $-869.46 |
-0.639x | -295.24% |
| 2014-12-31 | GBX-1.19 Million ≈ $-144.55 |
GBX-389.00K ≈ $-47.33 |
0.327x | -59.54% |
| 2013-12-31 | GBX-949.00K ≈ $-115.47 |
GBX-768.00K ≈ $-93.44 |
0.809x | -70.13% |
| 2012-12-31 | GBX-837.00K ≈ $-101.84 |
GBX-2.27 Million ≈ $-275.95 |
2.710x | -- |
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. Its lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-ass… Read more